ScholarLens Back to search
2002•Clinical Infectious DiseasesRequires access

Atovaquone/Proguanil Therapy forPlasmodium falciparumandPlasmodium vivaxMalaria in Indonesians Who Lack Clinical Immunity

Mark D. Lacy, Jason D. Maguire, Mazie J. Barcus, Judith Ling, Michael John Bangs, Robert A. Gramzinski, Hasan Basri, Priyanto Sismadi, Gerri B. Miller, Jeffrey David Chulay, David J. Fryauff, Stephen L. Hoffman, J. Kevin Baird

Open publisher page 34 citations

Abstract

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.

About this research paper

What this paper is about

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.

Why it matters

OpenAlex reports 34 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.

Key concepts: Proguanil, Atovaquone, Medicine, Malaria, Plasmodium falciparum, Plasmodium vivax, Malaria prophylaxis, Placebo

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Atovaquone/Proguanil Therapy forPlasmodium falciparumandPlasmodium vivaxMalaria in Indonesians Who Lack Clinical Immunity — Research Paper | ScholarLens